6+ day, 18+ hour ago  (364+ words) In SELVA Phase 3 study, 100% of participants (13/13) aged 611 years were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the Microcystic Lymphatic Malformation Investigator Global Assessment (m LM-IGA) scale at Week 24, with a mean improvement of +2. 46 (p 87% of participants (20/23) in SELVA…...

1+ mon, 1+ week ago  (248+ words) James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4: 30 p. m. ET WAYNE, Pa. , April. .. Palvella Therapeutics to Present QTORIN" Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA…...

3+ week, 2+ day ago  (712+ words) Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50, 000 diagnosed patients in the U. S. Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN" Rapamycin for…...

3+ hour, 10+ min ago  (634+ words) Yale-licensed U. S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial. .. Palvella Therapeutics Strengthens QTORIN" Pitavastatin Intellectual Property with Yale-Licensed U. S. Patent Providing Protection into 2043 Yale-licensed U. S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis,…...

1+ mon, 1+ hour ago  (449+ words) Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U. S. Food and…...

1+ week, 1+ day ago  (584+ words) Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall Patent strengthens intell. .. Autonomix Medical, Inc. Granted U. S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation Technology unlocks minimally invasive transvascular…...

2+ week, 5+ day ago  (134+ words) Cardiol Therapeutics ( (TSE: CRDL) ) has issued an update. The most recent analyst rating on (TSE: CRDL) stock is a Buy with a C$8. 00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:…...

23+ hour, 17+ min ago  (170+ words) Live Presentation and Q&A: Thursday, May 28, 2026, 12 PM EDT "We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology," said Robert Bitterman, CEO and…...

1+ mon, 4+ day ago  (129+ words) Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDT "We look forward to sharing why we believe INTASYL represents a differentiated approach to immuno-oncology and our strategy for PH-762 as we plan for the next stage of development," said Robert Bitterman,…...

18+ hour, 35+ min ago  (571+ words) Collaborative R&D at Applied's EPIC Center in Silicon Valley will enable higher yields and faster commercialization of next-generation chips Pa. .. Applied Materials Partners with SCREEN To Bring Advanced Wafer Cleaning Technologies to EPIC Center - Collaborative R&D at Applied's…...